FibroBiologics, Inc. (NASDAQ:FBLG) Short Interest Up 7.2% in November

FibroBiologics, Inc. (NASDAQ:FBLG - Get Free Report) was the target of a large increase in short interest in November. As of November 15th, there was short interest totalling 2,530,000 shares, an increase of 7.2% from the October 31st total of 2,360,000 shares. Approximately 9.4% of the company's stock are sold short. Based on an average trading volume of 402,500 shares, the short-interest ratio is currently 6.3 days.

FibroBiologics Trading Down 4.1 %

NASDAQ:FBLG traded down $0.11 during midday trading on Tuesday, reaching $2.60. The company had a trading volume of 102,327 shares, compared to its average volume of 253,066. FibroBiologics has a 12-month low of $1.08 and a 12-month high of $55.00. The stock's fifty day simple moving average is $2.88 and its 200-day simple moving average is $4.32.

Analysts Set New Price Targets

A number of research analysts have weighed in on FBLG shares. Maxim Group began coverage on FibroBiologics in a report on Tuesday, September 24th. They set a "buy" rating and a $12.00 target price for the company. HC Wainwright reissued a "buy" rating and issued a $12.00 target price on shares of FibroBiologics in a research report on Wednesday, November 13th. EF Hutton Acquisition Co. I raised FibroBiologics to a "strong-buy" rating in a research note on Wednesday, September 4th. Finally, D. Boral Capital reaffirmed a "buy" rating and issued a $16.00 price objective on shares of FibroBiologics in a research note on Wednesday, November 20th.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of FBLG. The Manufacturers Life Insurance Company purchased a new position in FibroBiologics in the 3rd quarter valued at about $32,000. Mercer Global Advisors Inc. ADV acquired a new position in FibroBiologics during the 2nd quarter worth $51,000. Jane Street Group LLC bought a new position in shares of FibroBiologics during the 3rd quarter worth about $37,000. Cahaba Wealth Management Inc. bought a new stake in FibroBiologics during the second quarter worth about $73,000. Finally, Saxon Interests Inc. bought a new stake in FibroBiologics in the second quarter valued at approximately $106,000.

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.